Original CJC-1295
Original CJC-1295 is a synthetic, tetrasubstituted peptide analog of endogenous growth hormone-releasing hormone (GHRH 1-29) designed to extend enzymatic half-life and stimulate anterior pituitary somatotrophs. Engineered for heightened structural stability against rapid peptidase degradation, this research compound is utilized in preclinical models investigating sustained somatotropic signaling and downstream insulin-like growth factor 1 (IGF-1) secretion.
Quick answer
Original CJC-1295 is a synthetic, tetrasubstituted peptide analog of endogenous growth hormone-releasing hormone (GHRH 1-29) designed to extend enzymatic half-life and stimulate anterior pituitary somatotrophs. Engineered for heightened structural stability against rapid peptidase degradation, this research compound is utilized in preclinical models investigating sustained somatotropic signaling and downstream insulin-like growth factor 1 (IGF-1) secretion.
Key takeaways
- Original [CJC-1295](/research-peptides/cjc-1295-no-dac) is a 29-amino-acid synthetic peptide analog of growth hormone-releasing hormone (GHRH) featuring four specific amino acid substitutions at positions 2, 8, 15, and 27.
- The molecular architecture of original [CJC-1295](/research-peptides/cjc-1295-no-dac) is derived from the functional N-terminal fragment of native human GHRH, known as [sermorelin](/research-peptides/sermorelin) or GHRH 1-29.
- Within scientific literature and catalog terminology, the designation 'original [CJC-1295](/research-peptides/cjc-1295-no-dac)' can create confusion regarding the presence of the Drug Affinity Complex (DAC).
- Original [CJC-1295](/research-peptides/cjc-1295-no-dac) functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a class B G-protein-coupled receptor predominantly localized on the cell surface of anterior pituitary somatotrophs.
Direct Answer: What Is Original CJC-1295?
Original CJC-1295 is a 29-amino-acid synthetic peptide analog of growth hormone-releasing hormone (GHRH) featuring four specific amino acid substitutions at positions 2, 8, 15, and 27. These chemical modifications protect the peptide backbone from rapid cleavage by dipeptidyl peptidase-IV (DPP-IV) and endopeptidases, dramatically lengthening its biological activity relative to native GHRH 1-29.
In preclinical laboratory settings, original CJC-1295 is studied as a targeted secretagogue that binds to the pituitary GHRH receptor to stimulate endogenous growth hormone (GH) release. Its altered pharmacokinetics allow researchers to evaluate prolonged somatotropic activation and downstream hepatic IGF-1 expression without requiring frequent re-administration during longitudinal cell culture or animal assays.
Chemical Structure and Tetrasubstitution Chemistry
The molecular architecture of original CJC-1295 is derived from the functional N-terminal fragment of native human GHRH, known as sermorelin or GHRH 1-29. Native GHRH 1-29 exhibits an extremely short plasma half-life in biological systems—often under twelve minutes—due to aggressive degradation by the ubiquitous circulating enzyme DPP-IV, which cleaves the peptide between Alanine at position 2 and Aspartic Acid at position 3.
To bypass this systemic bottleneck, medicinal chemists introduced four selective amino acid substitutions into the 29-residue sequence: D-Alanine at position 2, Glutamine at position 8, Alanine at position 15, and Leucine at position 27. The incorporation of D-Ala2 sterically hinders DPP-IV binding, while the remaining substitutions stabilize the alpha-helical secondary structure and reduce oxidative or thermal degradation. Researchers evaluating GHRH analogs utilize this modified peptide backbone to maintain receptor occupancy over extended experimental windows.
CJC-1295 With DAC vs. Without DAC: Resolving Nomenclature Confusion
Within scientific literature and catalog terminology, the designation 'original CJC-1295' can create confusion regarding the presence of the Drug Affinity Complex (DAC). When the molecule was originally synthesized by ConjuChem Biotechnologies, the primary construct featured a reactive maleimido-propionic acid linker appended to the C-terminus (Lys30). This reactive moiety allows the peptide to covalently bind to circulating serum albumin post-administration, creating what is officially recognized as CJC-1295 DAC.
Conversely, the tetrasubstituted sequence without the reactive C-terminal DAC linker is technically classified as Modified GRF 1-29 (also cataloged as Mod GRF 1-29). However, many historical laboratory papers and supply databases refer to the modified tetrasubstituted chain lacking DAC as 'original CJC-1295' or 'CJC-1295 No DAC.' Understanding this distinction is critical for laboratory investigators: the DAC-conjugated variant exhibits an extended half-life measured in days due to albumin recycling, whereas the non-DAC tetrasubstituted form exhibits a plasma half-life of approximately 30 minutes, maintaining a more discrete, pulsatile release profile when evaluated in vitro or in vivo.
Mechanism of Action and GHRH Receptor Affinity
Original CJC-1295 functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a class B G-protein-coupled receptor predominantly localized on the cell surface of anterior pituitary somatotrophs. Binding of the peptide to GHRHR activates the heterotrimeric Gs protein subunit, which subsequently stimulates membrane-bound adenylyl cyclase.
This enzymatic activation converts intracellular adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). Rising cAMP concentrations activate protein kinase A (PKA), leading to the phosphorylation of L-type voltage-gated calcium channels and influx of extracellular Ca2+. Elevated cytosolic calcium levels trigger exocytosis of pre-stored growth hormone granules into the surrounding medium. Simultaneously, PKA phosphorylates cAMP response element-binding protein (CREB), promoting gene transcription of new GH mRNA. Preclinical models demonstrate that original CJC-1295 sustains this signaling cascade without inducing rapid receptor desensitization or downregulation when calibrated within physiological boundaries.
Preclinical Research Findings: GH Dynamics and Downstream IGF-1
In vitro assays and rodent studies indicate that original CJC-1295 alters the total area under the curve (AUC) for circulating growth hormone while preserving baseline feedback loops. In animal models, administration of tetrasubstituted GHRH analogs results in dose-dependent elevations of both total GH amplitude and total secretagogue output. Unlike direct administration of recombinant GH, which suppresses endogenous pituitary production via negative feedback, GHRH analogs preserve the natural responsiveness of somatotrophs to endogenous somatostatin inhibitor signals.
A major primary endpoint in somatotropic research is the secondary secretion of insulin-like growth factor 1 (IGF-1) from hepatocytes. Preclinical data show that sustained exposure to original CJC-1295 induces a prolonged, multi-day elevation of systemic IGF-1 levels. Because IGF-1 serves as a master regulator of protein synthesis, cellular proliferation, and extracellular matrix remodeling, this compound is heavily utilized in experimental research investigating muscle tissue regeneration, skeletal integrity, and metabolic homeostasis.
Comparative Analysis: Original CJC-1295 vs. Sermorelin vs. Ipamorelin
When designing secretagogue protocols, investigators frequently compare original CJC-1295 against other prominent compounds within the somatotropic class. Native sermorelin retains the baseline 1-29 sequence without tetrasubstitution, making it highly susceptible to DPP-IV cleavage and limiting its operational half-life to approximately 10 to 12 minutes in serum. As detailed in our comprehensive CJC-1295 vs. Sermorelin comparative study, the structural modifications in original CJC-1295 afford significantly greater metabolic stability and higher total GH secretion per molar unit.
In contrast, peptides like ipamorelin act through an entirely distinct molecular pathway: the growth hormone secretagogue receptor (GHSR-1a), or ghrelin receptor. While original CJC-1295 stimulates the GHRH receptor pathway, ghrelin mimetics stimulate GH release via phospholipase C and intracellular calcium mobilization. Research protocols often investigate dual-agonist models combining a GHRH analog with a GHRP to observe synergistic pituitary secretion, as the simultaneous activation of both receptor pathways yields a far greater release of GH than either agent tested in isolation. All of these variants are indexed across our full catalog of research peptides for comparative evaluation.
Reconstitution and Handling Protocols for Laboratory Settings
Original CJC-1295 is supplied as a sterile, lyophilized cake to ensure maximum chemical stability during transit and long-term storage. Lyophilized peptide vials should be kept in a sub-zero freezer environment (typically -20°C to -80°C) away from light exposure prior to reconstitution. Under these cold-chain conditions, the un-reconstituted powder retains structural integrity for extended periods.
For laboratory reconstitution, researchers should utilize bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline depending on downstream assay compatibility. The diluent must be introduced slowly down the interior glass wall of the vial to minimize shear force and prevent foam formation or aggregation. Gentle swirling is recommended; vortexing or aggressive agitation should be strictly avoided to prevent physical denaturation of the secondary alpha-helical peptide structure. Once reconstituted, liquid solutions should be stored at 2°C to 8°C and used within a defined experimental window to avoid hydrolysis or micro-precipitation.
Analytical Verification: HPLC, Mass Spectrometry, and Endotoxin Standards
To generate reproducible, peer-reviewable data, laboratory researchers require research compounds verified by rigorous chemical analytics. Unpurified or improperly synthesized peptides may contain truncation sequences, missing amino acid residues, residual trifluoroacetic acid (TFA) salts, or heavy metal contamination that corrupts cellular assays and alters receptor binding kinetics.
Every production batch of original CJC-1295 from PX1 Research undergoes strict analytical validation. Purity is verified using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a baseline chemical purity exceeding 99.0%. Molecular weight and precise amino acid sequencing are confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS). Furthermore, because bacterial endotoxins can induce non-specific inflammatory signaling in cell culture and animal models, each lot is subjected to Chromogenic Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels remain far below standard preclinical safety thresholds. Researchers can review lot-specific documentation within our published research library.
Sourcing Standards for Preclinical Research: The PX1 Commitment
Sourcing high-purity research materials is a foundational prerequisite for high-impact laboratory investigation. Substandard reagents introduce unquantifiable variables that compromise experimental reproducibility, alter receptor binding kinetics, and waste valuable laboratory resources. PX1 Research manufactures all compounds in state-of-the-art, GMP-compliant facilities operating within the United States.
Our analytical testing is conducted independently by ISO 17025 accredited testing laboratories. Every single lot is accompanied by a publicly accessible Certificate of Analysis (COA) containing raw HPLC chromatograms and mass spectra. To support uninterrupted laboratory workflows, PX1 Research provides same-day dispatch for orders placed Monday through Friday, shipping directly from specialized distribution facilities in California and Arizona. University laboratories, biotechnology organizations, and institutional researchers requiring bulk quantities can apply for dedicated account terms via our wholesale research portal.
Frequently Asked Questions
What is the key difference between original CJC-1295 with DAC and without DAC?
Original CJC-1295 with DAC contains a reactive C-terminal maleimide group that covalently binds to circulating serum albumin, extending its biological half-life to several days. Without DAC (frequently termed Mod GRF 1-29), the tetrasubstituted peptide has a shorter half-life of approximately 30 minutes, producing more discrete, pulsatile secretagogue dynamics in laboratory models.
How does tetrasubstitution protect original CJC-1295 from enzymatic degradation?
The substitution of D-Alanine at position 2 sterically prevents dipeptidyl peptidase-IV (DPP-IV) from cleaving the N-terminal active site. Additional substitutions at positions 8, 15, and 27 enhance resistance to oxidation and endopeptidase cleavage, maintaining alpha-helical structural stability in biological media.
What analytical tests verify the purity of PX1 Research CJC-1295?
Every lot undergoes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm purity ≥99.0%, Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular mass, and Chromogenic LAL assaying to ensure low endotoxin levels.
How should lyophilized original CJC-1295 be stored upon receipt?
Lyophilized vials should be stored in a dry, dark freezer environment at -20°C or colder. Under these conditions, the dry peptide cake maintains chemical stability and resists degradation over extended storage periods.
What solvent is recommended for reconstituting CJC-1295 for in vitro protocols?
Bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline is standard for laboratory reconstitution. The diluent should be allowed to run gently down the glass wall of the vial without aggressive shaking or vortexing.
Can original CJC-1295 be combined with ghrelin receptor agonists in research assays?
Yes. In preclinical literature, GHRH analogs like CJC-1295 are frequently co-administered with GHRP class secretagogues (such as ipamorelin or GHRP-6) to investigate synergistic, dual-pathway growth hormone stimulation on somatotroph cultures.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are manufactured in GMP-compliant facilities within the United States. Orders are dispatched same-day (Monday through Friday) from our logistics nodes located in California and Arizona.
Is original CJC-1295 approved for clinical or therapeutic use in humans?
No. Original CJC-1295 is strictly a research compound intended exclusively for laboratory, in vitro, and preclinical research applications. It is not for human consumption, therapeutic treatment, or clinical use.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.